Map making in the 21st century: Charting breast cancer susceptibility pathways in rodent models

Journal of Mammary Gland Biology and Neoplasia

Volumn 16, Issue 1, 2011, Pages 57-64

  Blackburn, Anneke C ^a   Jerry, D Joseph ^b,c  

^a Australian National University   (Australia)

^b Pioneer Valley Life Sciences Institute   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Animal models; Breast cancer; Genetic mapping; Modifier genes; P53

Indexed keywords

HORMONE;

ALLELE; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER RESISTANCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOGENICITY; DIET; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENETIC VARIABILITY; GENETICS; HEREDITY; HUMAN; NONHUMAN; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959618711     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-011-9201-9     Document Type: Article

References (59)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005;34:405-12. (Pubitemid 40645331)
3. Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003;237:474-82. (Pubitemid 38176426)
4. Dunphy KA, Blackburn AC, Yan H, O'Connell LR, Jerry DJ. Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/? mice. Breast Cancer Res. 2008;10:R43.
5. Jerry DJ, Dunphy KA, Hagen MJ. Estrogens, regulation of p53 and breast cancer risk: a balancing act. Cell Mol Life Sci. 2010;67:1017-23.
6. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78-85. (Pubitemid 30451850)
7. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene. 2006;25:5898-905. (Pubitemid 44453445)
8. Ponder BA. Cancer genetics. Nature. 2001;411:336-41. (Pubitemid 32467042)
9. Land CE. Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer. JAMA. 1995;274:402-7.
10. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 1997;79:1203-10. (Pubitemid 27118218)
11. Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008;299:194-201.
12. van der Kolk DM, de Bock GH, Leegte BK, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 2010;124:643-51.
13. Hunter KW, Crawford NP. The future of mouse QTL mapping to diagnose disease in mice in the age of whole-genome association studies. Annu Rev Genet. 2008;42:131-41.
14. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20: 4621-8. (Pubitemid 32762434)
15. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997;150:1-13. (Pubitemid 27027090)
16. Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82:1932-7. (Pubitemid 30326453)
17. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 1992;356:215-21.
18. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4:1-7.
19. Donehower LA, Harvey M, Vogel H, et al. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog. 1995;14:16-22.
20. Blackburn AC, Brown JS, Naber SP, Otis CN, Wood JT, Jerry DJ. BALB/c alleles for Prkdc and Cdkn2a interact to modify tumor susceptibility in Trp53+/? mice. Cancer Res. 2003;63:2364-8. (Pubitemid 36605169)
21. Kuperwasser C, Hurlbut GD, Kittrell FS, et al. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice: a model for Li-fraumeni syndrome. Am J Pathol. 2000;157:2151-9.
22. Backlund MG, Trasti SL, Backlund DC, Cressman VL, Godfrey V, Koller BH. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice. Cancer Res. 2001;61:6577-82. (Pubitemid 32783267)
23. Blackburn AC, Hill LZ, Roberts AL, et al. Genetic mapping in mice identifies DMBT1 as a candidate modifier of mammary tumors and breast cancer risk. Am J Pathol. 2007;170:2030-41. (Pubitemid 47339276)
24. Koch JG, Gu X, Han Y, et al. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome. 2007;18:300-9. (Pubitemid 47106845)
25. Tchatchou S, Riedel A, Lyer S, et al. Identification of a DMBT1 polymorphism associated with increased breast cancer risk and decreased promoter activity. Hum Mutat. 2009;31:60-6.
26. Szpirer C, Szpirer J. Mammary cancer susceptibility: human genes and rodent models. Mamm Genome. 2007;18:817-31. (Pubitemid 50006520)
27. Gould MN. The utility of comparative genetics to inform breast cancer prevention strategies. Genetics. 2009;183:409-12.
28. Samuelson DJ, Aperavich BA, Haag JD, Gould MN. Fine mapping reveals multiple loci and a possible epistatic interaction within the mammary carcinoma susceptibility quantitative trait locus, Mcs5. Cancer Res. 2005;65:9637-42. (Pubitemid 41541438)
29. Samuelson DJ, Hesselson SE, Aperavich BA, et al. Rat Mcs5a is a compound quantitative trait locus with orthologous human loci that associate with breast cancer risk. Proc Natl Acad Sci USA. 2007;104:6299-304. (Pubitemid 47186089)
30. Winter SF, Hunter KW. Mouse modifier genes in mammary tumorigenesis and metastasis. J Mammary Gland Biol Neoplasia. 2008;13:337-42.
31. Lin EY, Jones JG, Li P, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003;163:2113-26. (Pubitemid 37310040)
32. Lifsted T, Le VT, Williams M, et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer. 1998;77:640-4. (Pubitemid 28340915)
33. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet. 2005;37:1055-62. (Pubitemid 41486657)
34. Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res. 2006;8(2):R16.
35. Hsieh SM, Look MP, Sieuwerts AM, Foekens JA, Hunter KW. Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. Breast Cancer Res. 2009;11(5):R75.
36. Quan X, Laes JF, Stieber D, et al. Genetic identification of distinct loci controlling mammary tumor multiplicity, latency, and aggressiveness in the rat. Mamm Genome. 2006;17:310-21.
37. Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. Breast Cancer Res. 2005;7:21-32. (Pubitemid 40214533)
38. Inano H, Suzuki K, Onoda M, Yamanouchi H. Susceptibility of fetal, virgin, pregnant and lactating rats for the induction of mammary tumors by gamma rays. Radiat Res. 1996;145:708-13. (Pubitemid 26159518)
39. Shellabarger CJ, Chmelevsky D, Kellerer AM. Induction of mammary neoplasms in the Sprague-Dawley rat by 430 keV neutrons and X-rays. J Natl Cancer Inst. 1980;64:821-33. (Pubitemid 10134486)
40. Ullrich RL. Tumor induction in BALB/c female mice after fission neutron or gamma irradiation. Radiat Res. 1983;93:506-15. (Pubitemid 13112276)
41. Mori N, Okumoto M, Hart AA, Demant P. Apoptosis susceptibility genes on mouse chromosome 9 (Rapop2) and chromosome 3 (Rapop3). Genomics. 1995;30:553-7. (Pubitemid 26038550)
42. Mori N, Okumoto M, van der Valk MA, et al. Genetic dissection of susceptibility to radiation-induced apoptosis of thymocytes and mapping of Rapop1, a novel susceptibility gene. Genomics. 1995;25:609-14.
43. Yu Y, Okayasu R, Weil MM, et al. Elevated breast cancer risk in irradiated BALB/c mice associates with unique functional polymorphism of the Prkdc (DNA-dependent protein kinase catalytic subunit) gene. Cancer Res. 2001;61:1820-4. (Pubitemid 32691991)
44. Umesako S, Fujisawa K, Iiga S, et al. Atm heterozygous deficiency enhances development of mammary carcinomas in p53 heterozygous knockout mice. Breast Cancer Res. 2005;7: R164-70.
45. Gould KA, Tochacek M, Schaffer BS, Reindl TM, Murrin CR, Lachel CM, et al. Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics. 2004;168:2113-25. (Pubitemid 40066348)
46. Schaffer BS, Lachel CM, Pennington KL, Murrin CR, Strecker TE, Tochacek M, et al. Genetic bases of estrogen-induced tumorigenesis in the rat: mapping of loci controlling susceptibility to mammary cancer in a Brown Norway x ACI intercross. Cancer Res. 2006;66:7793-800. (Pubitemid 44289240)
47. Gordon RR, Hunter KW, La Merrill M, Sørensen P, Threadgill DW, Pomp D. Genotype X diet interactions in mice predisposed to mammary cancer: II. Tumors and metastasis. Mamm Genome. 2008;19:179-89.
48. Gordon RR, La Merrill M, Hunter KW, Sørensen P, Threadgill DW, Pomp D. Dietary fat-dependent transcriptional architecture and copy number alterations associated with modifiers of mammary cancer metastasis. Clin Exp Metastasis. 2010;27:279-93.
49. Bahassi EM, Penner CG, Robbins SB, et al. The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model. Mutat Res. 2007;616:201-9. (Pubitemid 46198859)
50. Bahassi EM, Robbins SB, Yin M, et al. Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias. Proc Natl Acad Sci USA. 2009;106:17111-6.
51. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413-31.
52. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591-602. (Pubitemid 39535748)
53. Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, et al. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS ONE. 2010;5:e10813.
54. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 2007;26:1317-23. (Pubitemid 46328460)
55. Post SM, Quintas-Cardama A, Pant V, et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010;18:220-30.
56. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormonedependent manner. Cancer Res. 2006;66:5104-10. (Pubitemid 43844932)
57. Varghese JS, Easton DF. Genome-wide association studies in common cancers-what have we learnt? Curr Opin Genet Dev. 2010;20:201-9.
58. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70:9742-54.
59. Weitzel JN, Buys SS, Sherman WH, Daniels A, Ursin G, Daniels JR, et al. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res. 2007;13:654-8. (Pubitemid 46225373)